Minimal effects of dextroamphetamine on scopolamine-induced cognitive impairments in humans

Biological Psychiatry

Volumn 41, Issue 1, 1997, Pages 50-57

  Martinez, Rick ^a   Molchan, Susan E ^a,d   Lawlor, Brian A ^b   Thompson, Karen ^a   Martinson, Heidi ^a   Latham, Georgia ^a   Weingartner, Herbert ^c   Sunderland, Trey ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b ST JAMES S HOSPITAL   (Ireland)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

attention; cholinergic; dextroamphetamine; scopolamine; stimulant

Indexed keywords

DEXAMPHETAMINE; SCOPOLAMINE;

ADULT; ARTICLE; COGNITIVE DEFECT; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEMORY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031024943     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-3223(95)00674-5     Document Type: Article

References (41)

1. Angrist B, Corwin J, Bartlik B, Cooper T (1987): Early pharmacokinetics and clinical effects of oral d-amphetamine in normal subjects. Biol Psychiatry 22:1357-1368.
2. Bartus RT (1978): Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: Effects of concurrent administration of physostigmine and methylphenidate with scopolamine. Pharmacol Biochem Behav 9:833-836.
3. Battig W, Montague N (1969): Category norms for verbal items in 56 categories. J Exp Psychol Monogr 80:1-43.
4. Beatty WW, Butters N, Janowsky DS (1986): Patterns of memory failure after scopolamine treatment: Implications for cholinergic hypotheses of dementia. Behav Neural Biol 45: 196-211.
5. Breese GR, Cott JM, Cooper BR, Prange AJ, Lipton MA, Plotnikoff NP (1975): Effects of thyrotropin-releasing hormone (TRH) on the actions of pentobarbital and other centrally acting drugs. J Pharmacol Exp Ther 193:11-22.
6. Buschke H (1973): Selective reminding for analysis of memory and learning. J Verb Learn Verb Behav 12:543-550.
7. Coyle JT, Price DL, DeLong MR (1983): Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 219: 1184-1190.
8. Curran HV, Schifano F, Lader M (1991): Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood. Psychopharmacology 103:83-90.
9. Davis KL, Thal LJ, Gamzu ER, et al and Tacrine Collaborative Study Group (1992): A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 327:1253-1259.
10. Drachman DA (1977): Memory and cognitive function in man: Does the cholinergic system have a specific role? Neurology 27:783-790.
11. Drachman DA, Leavitt J (1974): Human memory and the cholinergic system. Arch Neurol 30:113-121.
12. Dunne MP, Hartley LR (1986): Scopolamine and the control of attention in humans. Psychopharmacology 89:94-97.
13. Flicker C, Serby M, Ferris SH (1990): Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed. Psychopharmacology 100:243-250.
14. Guy W (1976): Assessment Manual for Psychopharmacology. Washington, DC: U.S. Dept. of Health, Education, and Welfare.
15. Horita A, Carino MA, Lai H (1986): Pharmacology of thyrotropin-releasing hormone. Ann Rev Pharmacol Toxicol 26: 311-332.
16. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI for the Tacrine Study Group (1994): A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 271:985-991.
17. Kuczenski R (1983): Biochemical actions of amphetamine and other stimulants. In Stimulants: Neurochemical, Behavioral, and Clinical Perspectives. New York: Raven Press.
18. Latham GS, Martinez R, Sunderland T (1990): Computer system for monitoring drug effects in psychopharmacologic research. In Proceedings of the 14th Annual Symposium on Computer Applications in Medical Care. Washington, DC: SCAMC, Inc., pp 831-834.
19. McNair DM, Lorr M, Droppleman LF (1971): Manual for the Profile of Mood States. San Diego, CA: Educational and Industrial Testing Service.
20. Mewaldt SP, Ghoneim MM (1979): The effects of interactions of scopolamine, physostigmine and methamphetamine on human memory. Pharmacol Biochem Behav 10:205-210.
21. Molchan SE, Mellow AM, Lawlor BA, et al (1990): TRH attenuates scopolamine-induced memory impairment in humans. Psychopharmacology 100:84-89.
22. Molchan SE, Martinez RA, Hill JL, et al (1992a): Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Rev 17:215-226.
23. Molchan SE, Mellow AM, Hill JL, et al (1992b): The effects of thyrotropin-releasing hormone and scopolamine in Alzheimer's disease and normal volunteers. J Psychopharmacol 6:489-500.
24. Oka T, Hosoya E (1977): The different effect of humoral modulators of the morphine-and central nervous system stimulant-induced hyperactivity of rats. Neuropharmacology 16:115-119.
25. Okada M (1991): Effects of a new thyrotropin releasing hormone analogue, YM-14673, on the in vivo release of acetylcholine as measured by intracerebral dialysis in rats. J Neurochem 56:1544-1547.
26. Overall JE, Gorham DR (1962): The brief psychiatric rating scale. Psychol Rep 10:799-812.
27. Rapoport JL, Buchsbaum MS, Weingartner H, Zahn TP, Ludlow C, Mikkelsen EJ (1980): Dextroamphetamine: Its cognitive and behavioral effects in normal and hyperactive boys and normal men. Arch Gen Psychiatry 37:933-943.
28. Safer DJ, Allen RP (1971): The central effects of scopolamine in man. Biol Psychiatry 3:347-355.
29. Sahakian BJ, Owen AM, Morant NJ, Eagger SA (1993): Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: Assessment of attentional and mnemonic function using CANTAB. Psychopharmacology 110:395-401.
30. Sitaram N, Weingartner H, Gillin JC (1978): Human serial learning: Enhancement with arecholine and impairment with scopolamine. Science 201:274-277.
31. Stitzer ML, Griffiths RR, Liebson I (1978): Effects of d-amphetamine on speaking in isolated humans. Pharmacol Biochem Behav 9:57-63.
32. Sunderland T, Tariot PN, Weingartner H, et al (1986): Pharmacologic modelling of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 10:599-610.
33. Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA, Murphy DL (1987): Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls: A dose-response study. Arch Gen Psychiatry 44: 418-426.
34. Sunderland T, Weingartner H, Cohen RM, et al (1989): Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls. Psychopharmacology 99:129-133.
35. Suzuki T, Fujimoto K, Oohata H, Kawashima K (1989): Effects of TRH and DN-1417 on high potassium-evoked acetylcholine release from rat basal forebrain slices determined directly by radioimmunoassay. Gen Pharmacol 20:239-242.
36. Tariot PA, Sunderland T, Weingartner H, et al (1987): Cognitive effects of L-deprenyl in Alzheimer's disease. Psychopharmacology 91:489-495.
37. Wechsler D (1987): Wechsler Memory Scale - Revised Manual. San Antonio, TX: The Psychological Corp., Harcourt Brace Jovanovich, Inc.
38. Weingartner H, Grafman J, Boutelle W, Kaye W, Martin PR (1983): Forms of memory failure. Science 221:380-382.
39. Weingartner H, Burns S, Diebel R, LeWitt PA (1984): Cognitive impairments in Parkinson's disease: Distinguishing between effort-demanding and automatic cognitive processes. Psychiatry Res 11:223-235.
40. Yamamura M, Kinoshita K, Nakagawa H, Ishida R (1991): Pharmacological study of TA-0910, a new thyrotropin-releasing hormone (TRH) analog: Effects on experimental memory impairment in mice and rats. Jpn J Pharmacol 55:241-253.
41. Yamazaki N, Nagaoka N, Nagawa Y (1986): Effect of thyrotropin-releasing hormone and its analog DN-1417 on scopolamine-induced impairment of short-term memory in rats. Jpn J Psychopharmacol 6:359-366.